AU2016283020A1 - Treatment of nut midline carcinoma - Google Patents
Treatment of nut midline carcinoma Download PDFInfo
- Publication number
- AU2016283020A1 AU2016283020A1 AU2016283020A AU2016283020A AU2016283020A1 AU 2016283020 A1 AU2016283020 A1 AU 2016283020A1 AU 2016283020 A AU2016283020 A AU 2016283020A AU 2016283020 A AU2016283020 A AU 2016283020A AU 2016283020 A1 AU2016283020 A1 AU 2016283020A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- alkylene
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZJRDWDCTNDNSFP-KRWDZBQOSA-N CCc1nnc2[n]1-c([s]c(C)c1C)c1C(c(cc1)ccc1Cl)=N[C@H]2CC(OC(C)(C)C)=O Chemical compound CCc1nnc2[n]1-c([s]c(C)c1C)c1C(c(cc1)ccc1Cl)=N[C@H]2CC(OC(C)(C)C)=O ZJRDWDCTNDNSFP-KRWDZBQOSA-N 0.000 description 2
- 0 CC*(C(*)*(CC)OC(*C*(C)C(c1nnc(C)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccccc1)=O)C1CCCCC1 Chemical compound CC*(C(*)*(CC)OC(*C*(C)C(c1nnc(C)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccccc1)=O)C1CCCCC1 0.000 description 1
- DFASNEVYJDNAGA-IBGZPJMESA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CNC(CN1CCNCC1)=O)c1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CNC(CN1CCNCC1)=O)c1nnc(C)[n]-21 DFASNEVYJDNAGA-IBGZPJMESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185203P | 2015-06-26 | 2015-06-26 | |
| US62/185,203 | 2015-06-26 | ||
| PCT/US2016/039270 WO2016210275A1 (en) | 2015-06-26 | 2016-06-24 | Treatment of nut midline carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016283020A1 true AU2016283020A1 (en) | 2018-01-04 |
Family
ID=56409188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016283020A Abandoned AU2016283020A1 (en) | 2015-06-26 | 2016-06-24 | Treatment of nut midline carcinoma |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180193350A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3314005A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018520124A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180035785A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107787227A (cg-RX-API-DMAC7.html) |
| AR (1) | AR105124A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016283020A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017028178A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2989313A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1252062A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256186A (cg-RX-API-DMAC7.html) |
| MA (1) | MA42249A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017016337A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016210275A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| EP4629984A1 (en) * | 2022-12-06 | 2025-10-15 | BioVentures, LLC | Development of potent dual hdac/brd4 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| PL2902030T3 (pl) * | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
-
2016
- 2016-06-24 US US15/739,905 patent/US20180193350A1/en not_active Abandoned
- 2016-06-24 WO PCT/US2016/039270 patent/WO2016210275A1/en not_active Ceased
- 2016-06-24 JP JP2017563973A patent/JP2018520124A/ja active Pending
- 2016-06-24 AU AU2016283020A patent/AU2016283020A1/en not_active Abandoned
- 2016-06-24 HK HK18111394.9A patent/HK1252062A1/zh unknown
- 2016-06-24 MX MX2017016337A patent/MX2017016337A/es unknown
- 2016-06-24 CA CA2989313A patent/CA2989313A1/en not_active Abandoned
- 2016-06-24 EP EP16738292.8A patent/EP3314005A1/en not_active Withdrawn
- 2016-06-24 BR BR112017028178-3A patent/BR112017028178A2/en not_active Application Discontinuation
- 2016-06-24 AR ARP160101908A patent/AR105124A1/es unknown
- 2016-06-24 CN CN201680036201.4A patent/CN107787227A/zh active Pending
- 2016-06-24 MA MA042249A patent/MA42249A/fr unknown
- 2016-06-24 KR KR1020187000569A patent/KR20180035785A/ko not_active Withdrawn
-
2017
- 2017-12-07 IL IL256186A patent/IL256186A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017028178A2 (en) | 2018-08-28 |
| JP2018520124A (ja) | 2018-07-26 |
| AR105124A1 (es) | 2017-09-06 |
| CN107787227A (zh) | 2018-03-09 |
| MA42249A (fr) | 2018-05-02 |
| HK1252062A1 (zh) | 2019-05-10 |
| MX2017016337A (es) | 2018-11-22 |
| US20180193350A1 (en) | 2018-07-12 |
| EP3314005A1 (en) | 2018-05-02 |
| CA2989313A1 (en) | 2016-12-29 |
| WO2016210275A1 (en) | 2016-12-29 |
| KR20180035785A (ko) | 2018-04-06 |
| IL256186A (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016283020A1 (en) | Treatment of nut midline carcinoma | |
| Wang et al. | Methamphetamine activates toll-like receptor 4 to induce central immune signaling within the ventral tegmental area and contributes to extracellular dopamine increase in the nucleus accumbens shell | |
| Rodriguez et al. | Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis | |
| Efferson et al. | Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model | |
| Yan et al. | Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity | |
| RU2566821C2 (ru) | Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение | |
| Klinngam et al. | Inhibition of cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sjögren’s syndrome | |
| EA038337B1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| Shin et al. | Sertindole, a potent antagonist at dopamine D2 receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells | |
| Knight et al. | In vitro evaluation of [3H] CPPC as a tool radioligand for CSF-1R | |
| Barnett et al. | Neuromyelitis optica: not a multiple sclerosis variant | |
| AU2014361814A1 (en) | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders | |
| CA2681038A1 (en) | Kinase protein binding inhibitors | |
| Downer et al. | Tracing the history of the human translocator protein to recent neurodegenerative and psychiatric imaging | |
| WO2017156489A1 (en) | Inhibitors of creb-cbp interaction for treatment of leukemia | |
| Kim et al. | Screening of σ2 receptor ligands and in vivo evaluation of 11C-labeled 6, 7-Dimethoxy-2-[4-(4-methoxyphenyl) butan-2-yl]-1, 2, 3, 4-tetrahydroisoquinoline for potential use as a σ2 receptor brain PET tracer | |
| Rujitharanawong et al. | Systematic comparisons of various markers for mast cell activation in RBL-2H3 cells | |
| JPH05509315A (ja) | インドラクタムｖ及びその誘導体による神経保護 | |
| CN116251199A (zh) | 结合α-突触核蛋白聚集体的小分子探针及其用途 | |
| US20250170097A1 (en) | Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy | |
| TW202333704A (zh) | 用於治療腫瘤的藥物組合及其應用 | |
| Yang et al. | Novel Dual-Functional Half-Curcumin Analogues as a Fluorescent and PET Probe for β-Amyloid Imaging in the Alzheimer’s Disease APP/PS1 Model | |
| CN114173780A (zh) | 用于降低含有延伸的核苷酸重复序列的基因的有害活性的化合物 | |
| He et al. | Illuminating synucleinopathies: advances in α-synuclein PET tracer development for in vivo neuroimaging | |
| US20230141863A1 (en) | Small Molecule Inhibitors Targeting the Sodium Channel Tamoxifen Receptor and Uses Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |